JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Join SI Premium – FREE
JPMorgan downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Neutral with a price target of $115.00 (from $125.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $119.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Xior Student Housing NV (XIOR:BB) to Hold
- Deutsche Bank Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Hold
- Trimegah Bangun Persada Tbk PT (NCKL:IJ) PT Lowered to IDR1,750 at Citi
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
